Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants

2016 ◽  
Vol 18 (3) ◽  
pp. 405-414 ◽  
Author(s):  
E. Panagou ◽  
G. Zakout ◽  
J. Keshani ◽  
C. Smith ◽  
D. Irish ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Real Time ◽  
Cell Transplantation ◽  
Quantitative Pcr ◽  
Hematopoietic Stem Cell ◽  
Solid Organ ◽  
Hematopoietic Stem ◽  
Real Time Quantitative Pcr

scholarly journals Impact of CMV PCR Blips in Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation

2018 ◽  
Vol 4 (6) ◽  
pp. e355 ◽  
Author(s):  
Isabelle P. Lodding ◽  
Amanda Mocroft ◽  
Caspar da Cunha Bang ◽  
Finn Gustafsson ◽  
Martin Iversen ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Solid Organ ◽  
Hematopoietic Stem

Malignancy Following Solid Organ and Hematopoietic Stem Cell Transplantation

2009 ◽  
Vol 02 ◽  
pp. 49
Author(s):  
Angela Susanne Punnett ◽  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Immunosuppressive Agents ◽  
Solid Organ ◽  
Hematopoietic Stem ◽  
Post Transplant ◽  
Increased Risk

There is a growing appreciation of the increased risk for malignancy following solid organ and hematopoietic stem cell transplantation as the survival of these patient populations increases overall. The risk for malignancy is related to a complex interaction of type, degree, and duration of immunosuppression, viral status, and recipient age. Most of the malignancies documented are common in the general population but occur with increasing incidence and have significant implications for post-transplant surveillance. Post-transplant lymphoproliferative disorder is specific to the transplant population and remains a treatment challenge. The development of novel immunosuppressive agents, the use of individualized immunosuppressive regimens, and collaborative therapeutic trials are necessary to advance clinical care for these patients. This article will review the current issues around malignancy in the post-transplant patient population.

Sign in / Sign up

Export Citation Format

Share Document